Basilea Pharmaceutica AG (SWX:BSLN)

Market Cap	571.92M
Revenue (ttm)	208.54M
Net Income (ttm)	77.59M
Shares Out	12.13M
EPS (ttm)	5.82
PE Ratio	8.09
Forward PE	13.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,491
Average Volume	53,356
Open	47.15
Previous Close	47.15
Day's Range	47.00 - 48.10
52-Week Range	34.55 - 48.10
Beta	0.77
RSI	75.59
Earnings Date	Feb 18, 2025

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections. In addition, the compan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 164
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: BSLN

Financial Performance

In 2024, Basilea Pharmaceutica AG's revenue was 208.54 million, an increase of 32.30% compared to the previous year's 157.63 million. Earnings were 77.59 million, an increase of 642.45%.